T
Tribune Therapeutics
Developing novel medicines to treat fibrosis, regardless of the cause, tissue or diagnosis
About Tribune Therapeutics
Tribune Therapeutics is a preclinical-stage biopharmaceutical company, established in 2020, with operations in Stockholm, Sweden, and Oslo, Norway, dedicated to developing treatments for fibrotic diseases. The company was co-founded by Ole J Kaasbøll, Georg Vo Beiske, and Håvard Attramadal. Its scientific foundation stems from decades of research at Oslo University Hospital, particularly within the lab of Dr. Håvard Attramadal, which was further advanced by Dr. Ole J. Kaasbøll through a SPARK Norway project. Dr. Kaasbøll, a licensed MD with a PhD focused on CCN signaling, serves as the Chief Scientific Officer, while Georg Vo Beiske is the CEO.
The company's business model centers on the discovery and development of novel medicines targeting the root causes of fibrosis, a condition characterized by the formation of scar tissue that can lead to organ failure. Tribune's approach is considered tissue-agnostic, aiming to treat fibrosis regardless of the affected organ—be it the heart, kidneys, lungs, or liver. Its core strategy involves interrupting the signaling of the CCN protein family, which are central to the pro-fibrotic pathway. By co-opting natural mechanisms and leveraging new insights into these proteins, the company has demonstrated strong anti-fibrotic effects in animal models.
The lead candidate in Tribune's pipeline is TRX-44, an albumin-fusion protein designed to mimic the structure and function of the endogenous protein CCN5. CCN5 naturally blocks the pro-fibrotic effects of other CCN family members. This mechanism differentiates TRX-44 from previous approaches that targeted individual CCN proteins. The initial clinical focus for TRX-44 is idiopathic pulmonary fibrosis (IPF), a chronic lung disease with a poor prognosis. The company plans to initiate toxicology studies and aims to move TRX-44 into clinical trials in 2026.
Tribune Therapeutics launched from stealth in 2021 after being co-created by venture capital firms HealthCap and Novo Seeds (the early-stage investment arm of Novo Holdings). The company has successfully raised a total of approximately €37 million ($40.8 million) through seed and Series A funding rounds. A significant Series A round in March 2025, which raised €23 million, was led by LifeArc Ventures and included participation from new and existing investors such as Industrifonden, Investinor, HealthCap, and Novo Holdings. This capital is intended to advance TRX-44 toward clinical readiness and support the development of other programs in its pipeline.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Mar 2025 | $30M | $119M | Investinor · Innovestor · Industrifonden · Novo Holdings | ↗ |
| SEED✓Equity / VC | Sep 2024 | $11M | $44M | HealthCap · Novo Holdings · Inven2 · Innovestor | ↗ |
Growth signals
Latest recorded traffic for Tribune Therapeutics is 170 monthly website visits, down 88.7% over the last three months. Tribune Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Tribune Therapeutics in the Stockholm ecosystem
The Tribune Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
HealthCap
Novo Holdings
Inven2
Innovestor
Series A3 investors entered at this stage
LifeArc Ventures
Investinor
Industrifonden
Other known investors2 additional known investors
University of Oslo
ShareLab
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tribune Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tribune Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









